drugset / Trial / NCT00421655

A Trial of Grazax in Subjects With Hayfever

NCT00421655

Phase 3 Completed 329 enrolled ALK-Abelló A/S
RandomizedParallel-groupTriple-blindTreatment

Summary

The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.

Timeline

Start
2006-12
Primary completion
2007-08
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Grazax Other / unclassified 75000 unknown Oral

Indications